Literature DB >> 22872542

The influence of overweight and obesity on maternal soluble fms-like tyrosine kinase 1 and its relationship with leptin during pregnancy.

Jennifer K Straughen1, Dawn P Misra, Pawan Kumar, Vinod K Misra.   

Abstract

We studied obesity-related differences in the relation of maternal levels of leptin to levels of soluble fms-like tyrosine kinase 1 (sFlt1), an antiangiogenic protein that influences placentation and risk of adverse pregnancy outcomes. In a prospective cohort of 286 gravidas, we measured maternal serum levels of sFlt1 and leptin at 5 time points across pregnancy. Analyses stratified on prepregnancy body mass index (<25 vs ≥25) were done using mixed linear models. The mean leptin concentrations were significantly higher in overweight/obese compared to normal-weight women, while mean sFlt1 levels in second and third trimester were significantly higher in normal weight compared to overweight/obese women. The relationship between sFlt1 and leptin differed between the 2 strata. After controlling for maternal weight, a 1 ng/mL increase in leptin was associated with an 19.4 pg/mL increase in sFlt1 (P = .01) in normal-weight women, while leptin was not associated with sFlt1 (β = 1.1, P = .75) in overweight/obese women. Such differences suggest that metabolic differences in overweight/obese women compared to their normal weight peers may differentially impact the physiologic changes during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22872542      PMCID: PMC3676260          DOI: 10.1177/1933719112452472

Source DB:  PubMed          Journal:  Reprod Sci        ISSN: 1933-7191            Impact factor:   3.060


  38 in total

1.  Circulating oxidized low-density lipoprotein and paraoxonase activity in preeclampsia.

Authors:  H Uzun; A Benian; R Madazli; M A Topçuoğlu; S Aydin; M Albayrak
Journal:  Gynecol Obstet Invest       Date:  2005-07-26       Impact factor: 2.031

2.  Serum leptin levels in preeclamptic pregnant women: relationship to thyroid-stimulating hormone, body mass index, and proteinuria.

Authors:  Alparslan Baksu; Arzu Ozkan; Nimet Goker; Başak Baksu; Aygul Uluocak
Journal:  Am J Perinatol       Date:  2005-04       Impact factor: 1.862

3.  Increased leptin levels in preeclampsia: associations with BMI, estrogen and SHBG levels.

Authors:  Michael Acromite; Mary Ziotopoulou; Christine Orlova; Christos Mantzoros
Journal:  Hormones (Athens)       Date:  2004 Jan-Mar       Impact factor: 2.885

4.  Leptin: a potential marker of placental insufficiency.

Authors:  Jacques Lepercq; Michèle Guerre-Millo; Jocelyne André; Michèle Caüzac; Sylvie Hauguel-de Mouzon
Journal:  Gynecol Obstet Invest       Date:  2003       Impact factor: 2.031

Review 5.  Adipocyte dysfunctions linking obesity to insulin resistance and type 2 diabetes.

Authors:  Adilson Guilherme; Joseph V Virbasius; Vishwajeet Puri; Michael P Czech
Journal:  Nat Rev Mol Cell Biol       Date:  2008-05       Impact factor: 94.444

6.  Maternal morbid obesity and the risk of adverse pregnancy outcome.

Authors:  Marie I Cedergren
Journal:  Obstet Gynecol       Date:  2004-02       Impact factor: 7.661

Review 7.  Adipokine dysregulation, adipose tissue inflammation and metabolic syndrome.

Authors:  E Maury; S M Brichard
Journal:  Mol Cell Endocrinol       Date:  2009-08-12       Impact factor: 4.102

8.  Reduced plasma adiponectin and elevated leptin in pre-eclampsia.

Authors:  Yanqiong Ouyang; Hanping Chen; Huizhen Chen
Journal:  Int J Gynaecol Obstet       Date:  2007-06-22       Impact factor: 3.561

9.  Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro.

Authors:  H Y Park; H M Kwon; H J Lim; B K Hong; J Y Lee; B E Park; Y Jang; S Y Cho; H S Kim
Journal:  Exp Mol Med       Date:  2001-06-30       Impact factor: 8.718

10.  Leptin, the product of Ob gene, promotes angiogenesis.

Authors:  A Bouloumié; H C Drexler; M Lafontan; R Busse
Journal:  Circ Res       Date:  1998-11-16       Impact factor: 17.367

View more
  7 in total

1.  High early pregnancy body mass index is associated with alterations in first- and second-trimester angiogenic biomarkers.

Authors:  Celeste Beck; Amanda Allshouse; Robert M Silver; William A Grobman; Hyagriv Simhan; David Haas; Uma M Reddy; Nathan R Blue
Journal:  Am J Obstet Gynecol MFM       Date:  2022-03-10

Review 2.  Increased risk for the development of preeclampsia in obese pregnancies: weighing in on the mechanisms.

Authors:  Frank T Spradley; Ana C Palei; Joey P Granger
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2015-10-07       Impact factor: 3.619

3.  Physical Activity and Risk of Preterm Birth in a Cohort of African American Women.

Authors:  Jennifer K Straughen; Shawnita Sealy-Jefferson; Michael Bazydlo; Laura Helmkamp; Dawn P Misra
Journal:  Womens Health Issues       Date:  2018-05-07

4.  Administration of recombinant human placental growth factor decreases blood pressure in obese hypertensive pregnant rats.

Authors:  Ana C Palei; Adelene Y Tan; Woo S Joo; Paul Kussie; Christopher D Anderson; Barbara A Wilson; Frank T Spradley
Journal:  J Hypertens       Date:  2020-11       Impact factor: 4.776

5.  Changes in adipose tissue distribution during pregnancy in overweight and obese compared with normal weight women.

Authors:  J K Straughen; S Trudeau; V K Misra
Journal:  Nutr Diabetes       Date:  2013-08-26       Impact factor: 5.097

6.  Body weight gain and serum leptin levels of non-overweight and overweight/obese pregnant women.

Authors:  Didier Silveira Castellano Filho; José Otávio do Amaral Correa; Plínio Dos Santos Ramos; Marina de Oliveira Montessi; Beatriz Julião Vieira Aarestrup; Fernando Monteiro Aarestrup
Journal:  Med Sci Monit       Date:  2013-11-22

Review 7.  Mechanisms of Endothelial Dysfunction in Pre-eclampsia and Gestational Diabetes Mellitus: Windows Into Future Cardiometabolic Health?

Authors:  Colm J McElwain; Eszter Tuboly; Fergus P McCarthy; Cathal M McCarthy
Journal:  Front Endocrinol (Lausanne)       Date:  2020-09-11       Impact factor: 5.555

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.